Literature DB >> 21913800

New reagents for improved in vitro and in vivo examination of TGF-β signalling.

Rodney B Luwor1, Bo Wang, Thao V Nheu, Josephine Iaria, Evelyn Tsantikos, Margaret L Hibbs, Oliver M Sieber, Hong-Jian Zhu.   

Abstract

Transforming growth factor-β (TGF-β) signalling controls many aspects of cell behaviour and is implicated as a key regulator in tumour formation and progression. However, evaluating levels of active TGF-β in culture medium or patient plasma and gaining definitive information regarding the activity of downstream substrates such as Sma- and Mad-related protein 3 (Smad3) in vivo with accuracy and sensitivity has been problematic. Therefore, to overcome these technical issues we have created a NIH3T3 cell line with stable pCAGA(12)-luc expression that can now be utilised to detect TGF-β activity with high sensitivity. In addition, we have created an adenoviral Smad3 luciferase reporter construct pAd.CAGA(12)-luc to successfully infect cells for in vitro assays, or prior to injection into mice and used to measure transcriptional activity in vivo. Thus, the NIH3T3-pCAGA(12)-luc cell line and the pAd.CAGA(12)-luc adenovirus will be extremely useful tools to measure TGF-β signalling activity with far greater efficiency and reliability compared to original and currently used reagents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21913800     DOI: 10.3109/08977194.2011.615311

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  7 in total

1.  CXXC5 regulates differentiation of C2C12 myoblasts into myocytes.

Authors:  Guangming Li; Xiangli Ye; Xiyang Peng; Yun Deng; Wuzhou Yuan; Yongqing Li; Xiaoyang Mo; Xijun Wang; Yongqi Wan; Xianchu Liu; Tingfang Chen; Zhigang Jiang; Xiongwei Fan; Xiushan Wu; Yuequn Wang
Journal:  J Muscle Res Cell Motil       Date:  2014-11-30       Impact factor: 2.698

2.  SPSB1, a Novel Negative Regulator of the Transforming Growth Factor-β Signaling Pathway Targeting the Type II Receptor.

Authors:  Sheng Liu; Thao Nheu; Rodney Luwor; Sandra E Nicholson; Hong-Jian Zhu
Journal:  J Biol Chem       Date:  2015-06-01       Impact factor: 5.157

3.  Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.

Authors:  Nelson Ung; Tracy L Putoczki; Stanley S Stylli; Irvin Ng; John M Mariadason; Timothy A Chan; Hong-Jian Zhu; Rodney B Luwor
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

4.  Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System.

Authors:  Hao Chen; Thomas M B Ware; Josephine Iaria; Hong-Jian Zhu
Journal:  J Vis Exp       Date:  2018-07-30       Impact factor: 1.355

5.  Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo.

Authors:  R B Luwor; B Baradaran; L E Taylor; J Iaria; T V Nheu; N Amiry; C M Hovens; B Wang; A H Kaye; H-J Zhu
Journal:  Oncogene       Date:  2012-07-02       Impact factor: 9.867

6.  Single live cell TGF-β signalling imaging: breast cancer cell motility and migration is driven by sub-populations of cells with dynamic TGF-β-Smad3 activity.

Authors:  Rodney B Luwor; Dulani Hakmana; Josephine Iaria; Thao V Nheu; Richard J Simpson; Hong-Jian Zhu
Journal:  Mol Cancer       Date:  2015-02-22       Impact factor: 27.401

7.  Therapeutic Reversal of Radiotherapy Injury to Pro-fibrotic Dysfunctional Fibroblasts In Vitro Using Adipose-derived Stem Cells.

Authors:  Lipi Shukla; Rodney Luwor; Matthew E Ritchie; Shiva Akbarzadeh; Hong-Jian Zhu; Wayne Morrison; Tara Karnezis; Ramin Shayan
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-03-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.